A Population-based Analysis of the Rate of Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma in the United States

Urology

Volumn 74, Issue 4, 2009, Pages 837-841

  Jeldres, Claudio ^a,b   Baillargeon Gagne, Sara ^a,b   Liberman, Daniel ^a,b   Isbarn, Hendrik ^a,c   Capitanio, Umberto ^a,d   Shariat, Shahrokh F ^a   Sun, Maxine ^a   Lughezzani, Giovanni ^a,d   Perrotte, Paul ^b   Montorsi, Francesco ^d   Graefen, Markus ^c   Karakiewicz, Pierre I ^a,b  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^d VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE; AGED; ARTICLE; CANCER REGISTRY; CANCER SURVIVAL; CYTOREDUCTIVE NEPHRECTOMY; FEMALE; GENDER; GEOGRAPHICAL VARIATION (SPECIES); HUMAN; KIDNEY CARCINOMA; KIDNEY METASTASIS; MAJOR CLINICAL STUDY; MALE; NEPHRECTOMY; PRIORITY JOURNAL; RACE; TUMOR VOLUME; UNITED STATES;

AGED; AGED, 80 AND OVER; CARCINOMA, RENAL CELL; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEPHRECTOMY; SEER PROGRAM; UNITED STATES;

EID: 70349449730     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2009.04.019     Document Type: Article

References (21)

1. Flanigan R.C., Salmon S.E., Blumenstein B.A., et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 345 (2001) 1655-1659
2. Mickisch G.H., Garin A., van Poppel H., et al. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 358 (2001) 966-970
3. Negrier S., Perol D., Ravaud A., et al. Do cytokines improve survival in patients with metastatic renal cell carcinoma (MRCC) of intermediate prognosis?. Results of the prospective randomized Percy Quattro trial. J Clin Oncol 23 (2005) 4511
4. Zini L., Capitanio U., Perrotte P., et al. Population-based assessment of survival after cytoreductive nephrectomy versus no Surgery in patients with metastatic renal cell carcinoma. Urology 73 (2008) 342-346
5. Zini L., Perrotte P., Jeldres C., et al. Nephrectomy improves the survival of patients with locally advanced renal cell carcinoma. BJU Int 102 (2008) 1610-1614
6. Hankey B.F., Ries L.A., and Edwards B.K. The surveillance, epidemiology, and end results program: a national resource. Cancer Epidemiol Biomarkers Prev 8 (1999) 1117-1121
7. Cloutier V, Capitanio U, Zini L, et al. Thirty-day mortality after nephrectomy: clinical implications for informed consent. Eur Urol. (in press).
8. Kader A.K., Tamboli P., Luongo T., et al. Cytoreductive nephrectomy in the elderly patient: the M. D. Anderson Cancer Center experience. J Urol 177 (2007) 855-860 Discussion:860-861.
9. Eschwege P., Saussine C., Steichen G., et al. Radical nephrectomy for renal cell carcinoma 30 mm or less: long-term follow results. J Urol 155 (1996) 1196-1199
10. Hutterer G.C., Patard J.J., Perrotte P., et al. Patients with renal cell carcinoma nodal metastases can be accurately identified: external validation of a new nomogram. Int J Cancer 121 (2007) 2556-2561
11. Hutterer G.C., Patard J.J., Jeldres C., et al. Patients with distant metastases from renal cell carcinoma can be accurately identified: external validation of a new nomogram. BJU Int 101 (2008) 39-43
12. Morris G.J., and Mitchell E.P. Higher incidence of aggressive breast cancers in African-American women: a review. J Natl Med Assoc 100 (2008) 698-702
13. Zini L., Perrotte P., Capitanio U., et al. Race affects access to nephrectomy but not survival in renal cell carcinoma. BJU Int 103 (2008) 889-893
14. Berndt S.I., Carter H.B., Schoenberg M.P., et al. Disparities in treatment and outcome for renal cell cancer among older black and white patients. J Clin Oncol 25 (2007) 3589-3595
15. Gleave M.E., Elhilali M., Fradet Y., et al., Canadian Urologic Oncology Group. Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma. N Engl J Med 338 (1998) 1265-1271
16. Escudier B., Eisen T., Stadler W.M., et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356 (2007) 125-134
17. Motzer R.J., Hutson T.E., Tomczak P., et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356 (2007) 115-124
18. Hudes G., Carducci M., Tomczak P., et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356 (2007) 2271-2281
19. Motzer R.J., Mazumdar M., Bacik J., et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 17 (1999) 2530-2540
20. Motzer R.J., Bacik J., Schwartz L.H., et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 22 (2004) 454-463
21. Motzer R.J., Bacik J., Murphy B.A., et al. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 20 (2002) 289-296